top of page


State of the Nation Report: No Cancer Too Rare
In this State of Nation Report: No Cancer Too Rare, Cancer52 reviews policy developments since the 2024 General Election that will shape the next 10 years of cancer services. The report also reflects on what these developments means for our priorities for the UK Government and for making rare and less common cancers a priority in national policy.


Cancer52 Annual Review 2024-2025
Cancer52 is proud to share it's Annual Review covering April 2025 to March 2025. As ever it is fantastic to review what was achieved over the year. Read Cancer52 Annual Review 2024-2025


10 Year Health Plan for England, July 2025
Cancer52 welcomes the ambitions set out in the new 10 Year Health Plan for England, particularly its commitment to building a future-ready model of care that tackles health inequalities head-on. We hope that the resources will be able to match the ambitions.


Cancer52 Parliamentary Roundtable
Cancer52 hosted a Parliamentary Roundtable in the House of Commons on 24th February, hosted by Clive Jones MP.


Cancer52 Annual Review 2023-2024
Cancer52 is pleased to submit their Annual Review for the financial year 2023-2024 to the Charity Commission.


State of the Nation Report on Rare and Less Common Cancers
Released online for World Cancer Day on 4th February 2025, Cancer52 shared the 'State of the Nation report on Rare and Less Common Cancers.


Big Cancer52 Conversation, November 2024
Our fourth Big Cancer52 Conversation was held on 13th November in Canary Wharf, London.


Cancer52 Health Inequalities Report
Cancer52 has released its latest report on health inequalities , as part of the Big Cancer52 Conversation event. >> Read report...


Fair Market Value (FMV) Guidance
Fair Market Value (FMV) Guidance is now available to bring consistency to reimbursement for cross-sector partnership work. See FMV...


Cancer52's Manifesto 'The Other Half'
Cancer52 has launched a manifesto called ‘The Other Half. A manifesto to transform outcomes for people with rare and less common...
bottom of page
